TrueMark Investments LLC Purchases 7,349 Shares of Johnson & Johnson $JNJ

TrueMark Investments LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 23.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 38,591 shares of the company’s stock after purchasing an additional 7,349 shares during the quarter. Johnson & Johnson accounts for approximately 1.2% of TrueMark Investments LLC’s investment portfolio, making the stock its 26th largest holding. TrueMark Investments LLC’s holdings in Johnson & Johnson were worth $7,156,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of JNJ. Clark Asset Management LLC increased its stake in Johnson & Johnson by 51.6% in the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after acquiring an additional 3,025 shares during the period. Treasurer of the State of North Carolina boosted its holdings in Johnson & Johnson by 8.3% during the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after purchasing an additional 94,957 shares in the last quarter. Talbot Financial LLC grew its stake in shares of Johnson & Johnson by 4.6% in the 3rd quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock valued at $25,667,000 after purchasing an additional 6,143 shares during the period. Liberty One Investment Management LLC raised its holdings in shares of Johnson & Johnson by 83.9% in the 3rd quarter. Liberty One Investment Management LLC now owns 366,813 shares of the company’s stock worth $68,040,000 after buying an additional 167,353 shares in the last quarter. Finally, Winnow Wealth LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $295,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 beat, stronger guidance and rising free cash flow: JNJ beat Q4 revenue and EPS expectations, raised FY outlook and guided to materially higher 2026 free cash flow (~$21B), which underpins analyst upgrades and ETF buying interest. ETFs to Buy Post JNJ’s Q4 Earnings Surprise & Bullish Cash Flow View
• Positive Sentiment: Large Scotiabank upgrade: Scotiabank moved to “sector outperform” and raised its target sharply (to $265), signaling confidence in J&J’s growth runway and boosting investor appetite. Johnson & Johnson (JNJ) Gets a Buy from Scotiabank
• Positive Sentiment: Multiple price target raises from analysts: Leerink (+$201?$232) and Sanford C. Bernstein (+$208?$225) (and others including Stifel, BofA) have nudged targets higher, reflecting the quarter and helping push sentiment positive. Leerink Raises Price Target Bernstein Raises Price Target
• Positive Sentiment: Technical/trend signals: MarketBeat highlights a trend?following buy signal after a post?earnings pullback — technical confirmation can attract momentum and institutional flows. Trend?Following Buy Signal
• Positive Sentiment: MedTech strength and product pipeline: MedTech sales growth, product launches and the OTTAVA robotic submission provide a potential high?growth stream beyond staples like Stelara. MedTech Growth & Product Launches
• Neutral Sentiment: Valuation checks: Coverage pieces are assessing JNJ’s valuation after the rally — some see limited near?term upside from current levels, which could temper aggressive buying. Valuation After Momentum
• Negative Sentiment: Talc litigation risk: A Special Master allowed plaintiffs’ expert testimony in the talc MDL, keeping litigation risk visible and a potential earnings/cash?flow overhang. Talc Litigation Update

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Guggenheim upped their price target on Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a research report on Friday. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a report on Friday. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $226.18.

Johnson & Johnson Stock Up 0.8%

Shares of NYSE JNJ opened at $220.29 on Monday. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $222.17. The firm’s 50-day simple moving average is $208.35 and its 200 day simple moving average is $189.39. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company has a market cap of $530.74 billion, a price-to-earnings ratio of 19.94, a price-to-earnings-growth ratio of 2.14 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.46. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The company had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. During the same period in the previous year, the firm posted $2.04 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.